Gene Expression, Immunological Status and Metabolome in Glioma Patients

Study Overview
=================
Brief Summary
-----------------
Study on glioma patients treated with brain surgery is focusing on the analysis of their transcriptome expression profile measured in two immune cell populations, CD4+ T cells and CD56+ NK cells. The results of analysis will be compared to the reference data of healthy population. Furthermore, the metabolomic and immunological status will also be monitored and compared to healthy group reference data, before and after the surgery*. With comparative crossomics analysis the investigators intend to possibly identify new diagnostic and prognostic biological markers for the relapse of the disease. The results are expected to convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of the current surgical therapy. * The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).

Official Title
-----------------
Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients

Conditions
-----------------
Glioma

Intervention / Treatment
-----------------
* Procedure: Glioma resection
* Other: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: malignant glioma = glioblastoma (WHO IV) patients Exclusion Criteria: pregnancy metastases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glioma patients<br> | Procedure: Glioma resection<br>* Patients will be treated with the standard surgical therapy - glioma resection.<br>Other: Blood sampling<br>* Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transcriptome profile of CD4+ T and CD56+ NK cells |  | within 10 days before surgery | 
| Transcriptome profile of CD4+ T and CD56+ NK cells |  | one day after surgery | 
| Transcriptome profile of CD4+ T and CD56+ NK cells |  | within 10 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolite profiling in blood plasma samples |  | within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery | 
| Lymphocyte subpopulation assessment in peripheral blood samples |  | within 10 days before surgery, one day after surgery and once more within 10 days after surgery | 
| Antibody profiling in blood plasma samples |  | within 10 days before surgery, one day after surgery and once more within 10 days after surgery | 
| miRNA profiling in blood plasma samples |  | within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery | 
| Proteomic analysis of blood plasma samples |  | within 10 days before surgery, one day after surgery and once more within 10 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glioma, PBMC subpopulations, Gene expression, Metabolomics, Immunological status, miRNA, Proteomics